Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 110.22 +0.18 (+0.16%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Where Ligand Pharmaceuticals Stands With Analysts September 19, 2023 Via Benzinga Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio September 18, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Analyst Expectations for Ligand Pharmaceuticals's Future August 23, 2023 Via Benzinga Recap: Ligand Pharmaceuticals Q1 Earnings May 04, 2023 Via Benzinga Ligand Pharmaceuticals Earnings Preview February 21, 2023 Via Benzinga Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know December 23, 2022 Via Benzinga Ligand Reports Second Quarter 2023 Financial Results August 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials July 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand To Report Second Quarter 2023 Financial Results On August 8 July 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Why Are Novan Shares Nosediving Today? July 17, 2023 Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to Via Benzinga Ligand Offers $15 Million to Acquire Assets of Novan, Inc. July 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection July 17, 2023 From Novan, Inc. Via GlobeNewswire 3 Stocks That Smart Investors Should Be Flocking to Now May 30, 2023 Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. Via InvestorPlace Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial May 16, 2023 Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in Via Benzinga Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) May 16, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports First Quarter 2023 Financial Results May 04, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 April 24, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Fourth Quarter and Full Year 2022 Financial Results February 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment February 21, 2023 Via Benzinga Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Earnings Scheduled For February 22, 2023 February 22, 2023 Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. Via Benzinga Ligand to Report Fourth Quarter Financial Results on February 22 February 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum January 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tesla To $175? Here Are 10 Other Price Target Changes For Friday December 23, 2022 Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... Via Benzinga Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says December 16, 2022 Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. Via Benzinga Ligand Pharma Issues Mixed Guidance For FY23 December 13, 2022 At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... Via Benzinga Ligand Provides Highlights from its Investor and Analyst Day Event December 13, 2022 From Ligand Pharmaceuticals Via Business Wire Ligand Pharmaceuticals Names Director Todd C. Davis as CEO December 05, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
